Search Results - Ozgurdal, Kirhan

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

    Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety by Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky

    Published in Liver cancer (Basel )
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States

    Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States by Singal, Amit G, Özgürdal, Kirhan, Fan, Xiaozhou, Vassilev, Zdravko, Pan, Xiaoyun, Multani, Jasjit K, Chen, Chi-Chang, Zhou, Zifan, He, Jing, Pisa, Federica

    Published in Cancers
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

    Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study by Dane, Faysal, Ozgurdal, Kirhan, Yalçın, Şuayib, Benekli, Mustafa, Aykan, Nuri Faruk, Yücel, İdris, Özkan, Metin, Evrensel, Turkkan, Sevinç, Alper, Coskun, Hasan Şenol, Sanli, Ulus Ali, Kara, Ismail Oguz, Yumuk, Perran Fulden

    Published in BMJ open
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety

    Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety by Merle, Philippe, Kudo, Masatoshi, Krotneva, Stanimira, Ozgurdal, Kirhan, Su, Yun, Proskorovsky, Irina

    Published in Liver cancer (Basel )
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: